PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 30669396-8 2019 Cell viability and proliferation was significantly inhibited after incubation with EPA (50 and 100 muM) or DHA (100 muM). Eicosapentaenoic Acid 83-86 latexin Homo sapiens 99-102 19121632-4 2009 Chronic treatment (for 12 h) with EPA at lower concentrations (0.3-10 muM) increased the level of Kv1.5-FLAG protein as well as Kv1.5 channel current without changes in its gating kinetics, prolonging its half-life; in contrast, both EPA and DHA at higher concentrations (30-100 muM) decreased the expression of Kv1.5-FLAG. Eicosapentaenoic Acid 34-37 latexin Homo sapiens 70-73 19121632-4 2009 Chronic treatment (for 12 h) with EPA at lower concentrations (0.3-10 muM) increased the level of Kv1.5-FLAG protein as well as Kv1.5 channel current without changes in its gating kinetics, prolonging its half-life; in contrast, both EPA and DHA at higher concentrations (30-100 muM) decreased the expression of Kv1.5-FLAG. Eicosapentaenoic Acid 34-37 latexin Homo sapiens 279-282 32058033-12 2020 Both EPA and DHA (50 muM) significantly decreased cyclooxygenase (COX)-2 protein. Eicosapentaenoic Acid 5-8 latexin Homo sapiens 21-24 30669396-12 2019 We found that EPA and DHA (50 muM) decreased the phosphorylation levels of ERK1/2 and Akt in C2C12 myoblasts. Eicosapentaenoic Acid 14-17 latexin Homo sapiens 30-33 30669396-8 2019 Cell viability and proliferation was significantly inhibited after incubation with EPA (50 and 100 muM) or DHA (100 muM). Eicosapentaenoic Acid 83-86 latexin Homo sapiens 116-119 30669396-10 2019 RNA-sequencing analysis revealed that some muscle-related genes were significantly downregulated following EPA or DHA (50 muM) treatment, including insulin-like growth factor 2 (IGF-2), troponin T3 (Tnnt3), myoglobin (Mb), myosin light chain phosphorylatable fast skeletal muscle (Mylpf) and myosin heavy polypeptide 3 (Myh3). Eicosapentaenoic Acid 107-110 latexin Homo sapiens 122-125 29331380-7 2018 Conversely, DHA (10 muM) antioxidant benefit was lost by 4 h. At a lower concentration (5 muM), EPA antioxidant activity remained at 81% (5.53 +- 0.15 to 1.03 +- 0.10 muM MDA; p < .001) at 6 h, while DHA lost all antioxidant activity by 4 h. The antioxidant activity of EPA was preserved when combined with an equimolar concentration of DHA (5 muM each). Eicosapentaenoic Acid 96-99 latexin Homo sapiens 90-93 29331380-7 2018 Conversely, DHA (10 muM) antioxidant benefit was lost by 4 h. At a lower concentration (5 muM), EPA antioxidant activity remained at 81% (5.53 +- 0.15 to 1.03 +- 0.10 muM MDA; p < .001) at 6 h, while DHA lost all antioxidant activity by 4 h. The antioxidant activity of EPA was preserved when combined with an equimolar concentration of DHA (5 muM each). Eicosapentaenoic Acid 96-99 latexin Homo sapiens 90-93 29331380-6 2018 HDL oxidation was inhibited similarly by EPA and DHA up to 1 h. EPA (10 muM) maintained significant HDL oxidation inhibition of 89% (0.622 +- 0.066 muM MDA; p < .001) at 4 h, with continued inhibition of 64% at 14 h, vs. vehicle (5.65 +- 0.06 to 2.01 +- 0.10 muM MDA; p < .001). Eicosapentaenoic Acid 64-67 latexin Homo sapiens 72-75 29331380-7 2018 Conversely, DHA (10 muM) antioxidant benefit was lost by 4 h. At a lower concentration (5 muM), EPA antioxidant activity remained at 81% (5.53 +- 0.15 to 1.03 +- 0.10 muM MDA; p < .001) at 6 h, while DHA lost all antioxidant activity by 4 h. The antioxidant activity of EPA was preserved when combined with an equimolar concentration of DHA (5 muM each). Eicosapentaenoic Acid 96-99 latexin Homo sapiens 90-93 29331380-6 2018 HDL oxidation was inhibited similarly by EPA and DHA up to 1 h. EPA (10 muM) maintained significant HDL oxidation inhibition of 89% (0.622 +- 0.066 muM MDA; p < .001) at 4 h, with continued inhibition of 64% at 14 h, vs. vehicle (5.65 +- 0.06 to 2.01 +- 0.10 muM MDA; p < .001). Eicosapentaenoic Acid 64-67 latexin Homo sapiens 148-151 29331380-7 2018 Conversely, DHA (10 muM) antioxidant benefit was lost by 4 h. At a lower concentration (5 muM), EPA antioxidant activity remained at 81% (5.53 +- 0.15 to 1.03 +- 0.10 muM MDA; p < .001) at 6 h, while DHA lost all antioxidant activity by 4 h. The antioxidant activity of EPA was preserved when combined with an equimolar concentration of DHA (5 muM each). Eicosapentaenoic Acid 273-276 latexin Homo sapiens 90-93 29331380-6 2018 HDL oxidation was inhibited similarly by EPA and DHA up to 1 h. EPA (10 muM) maintained significant HDL oxidation inhibition of 89% (0.622 +- 0.066 muM MDA; p < .001) at 4 h, with continued inhibition of 64% at 14 h, vs. vehicle (5.65 +- 0.06 to 2.01 +- 0.10 muM MDA; p < .001). Eicosapentaenoic Acid 64-67 latexin Homo sapiens 148-151 29331380-7 2018 Conversely, DHA (10 muM) antioxidant benefit was lost by 4 h. At a lower concentration (5 muM), EPA antioxidant activity remained at 81% (5.53 +- 0.15 to 1.03 +- 0.10 muM MDA; p < .001) at 6 h, while DHA lost all antioxidant activity by 4 h. The antioxidant activity of EPA was preserved when combined with an equimolar concentration of DHA (5 muM each). Eicosapentaenoic Acid 273-276 latexin Homo sapiens 90-93 29331380-7 2018 Conversely, DHA (10 muM) antioxidant benefit was lost by 4 h. At a lower concentration (5 muM), EPA antioxidant activity remained at 81% (5.53 +- 0.15 to 1.03 +- 0.10 muM MDA; p < .001) at 6 h, while DHA lost all antioxidant activity by 4 h. The antioxidant activity of EPA was preserved when combined with an equimolar concentration of DHA (5 muM each). Eicosapentaenoic Acid 273-276 latexin Homo sapiens 90-93 28739279-6 2017 EPA 70muM reduced ABCA1-mediated cholesterol efflux to apolipoprotein (apo) AI by 30% without any alteration in ABCA1 expression. Eicosapentaenoic Acid 0-3 latexin Homo sapiens 6-9 27565090-10 2016 Besides, the viability and the thickness of mature P. gingivalis biofilm, together with the viability of mature F. nucleatum biofilm were both significantly decreased in the presence of 100 muM DHA or EPA. Eicosapentaenoic Acid 201-204 latexin Homo sapiens 190-193 27044314-6 2016 RESULTS: 50 muM, 10 muM EPA and 50 muM EPA + DHA decreased the expression of genes involved in the NF-kappaB pathway (MAPK, AKT1, and NFKB). Eicosapentaenoic Acid 24-27 latexin Homo sapiens 20-23 27044314-6 2016 RESULTS: 50 muM, 10 muM EPA and 50 muM EPA + DHA decreased the expression of genes involved in the NF-kappaB pathway (MAPK, AKT1, and NFKB). Eicosapentaenoic Acid 24-27 latexin Homo sapiens 20-23 27044314-7 2016 Treatment with 50 muM, 10 muM EPA, 50 muM DHA and EPA + DHA decreased expression levels of cytokines genes IL1Beta and MCP1. Eicosapentaenoic Acid 30-33 latexin Homo sapiens 26-29 27044314-7 2016 Treatment with 50 muM, 10 muM EPA, 50 muM DHA and EPA + DHA decreased expression levels of cytokines genes IL1Beta and MCP1. Eicosapentaenoic Acid 30-33 latexin Homo sapiens 26-29 27044314-7 2016 Treatment with 50 muM, 10 muM EPA, 50 muM DHA and EPA + DHA decreased expression levels of cytokines genes IL1Beta and MCP1. Eicosapentaenoic Acid 50-53 latexin Homo sapiens 18-21 27044314-7 2016 Treatment with 50 muM, 10 muM EPA, 50 muM DHA and EPA + DHA decreased expression levels of cytokines genes IL1Beta and MCP1. Eicosapentaenoic Acid 50-53 latexin Homo sapiens 26-29 26381084-3 2015 Therefore the aim of the study was to investigate whether EPA and DHA (25-100 muM) are able to reduce human lung cancer cell growth through oxidative stress influence on autophagy and apoptosis. Eicosapentaenoic Acid 58-61 latexin Homo sapiens 78-81 27044314-7 2016 Treatment with 50 muM, 10 muM EPA, 50 muM DHA and EPA + DHA decreased expression levels of cytokines genes IL1Beta and MCP1. Eicosapentaenoic Acid 50-53 latexin Homo sapiens 26-29 27044314-8 2016 TNFA expression was decreased by 50 muM, 10 muM of EPA, DHA and with 50 muM EPA + DHA. Eicosapentaenoic Acid 51-54 latexin Homo sapiens 44-47 27044314-8 2016 TNFA expression was decreased by 50 muM, 10 muM of EPA, DHA and with 50 muM EPA + DHA. Eicosapentaenoic Acid 51-54 latexin Homo sapiens 44-47 27044314-10 2016 50 muM of DHA and EPA + DHA inhibited PTGS2 expression when the two concentrations of EPA, 50 muM DHA and EPA + DHA inhibited ALOX5 expression. Eicosapentaenoic Acid 18-21 latexin Homo sapiens 94-97 26671842-7 2016 After a 72 h treatment with 150 muM DHA and EPA, or their combination (75/75 muM), growth rates were inhibited by 80.3 +- 5.5%, 79.3 +- 5% and 71.1 +- 1%, respectively, compared to untreated cells. Eicosapentaenoic Acid 44-47 latexin Homo sapiens 77-80 26671842-8 2016 We also found that treatment for 48 h with 100 muM DHA and EPA, or their combination (50/50 muM), resulted in 2.9-, 3- and 2.6-fold increases in caspase-3 activation, as well as 54, 62.4 and 100% decreases in survivin mRNA expression levels, respectively, compared to untreated cells. Eicosapentaenoic Acid 59-62 latexin Homo sapiens 47-50 26671842-8 2016 We also found that treatment for 48 h with 100 muM DHA and EPA, or their combination (50/50 muM), resulted in 2.9-, 3- and 2.6-fold increases in caspase-3 activation, as well as 54, 62.4 and 100% decreases in survivin mRNA expression levels, respectively, compared to untreated cells. Eicosapentaenoic Acid 59-62 latexin Homo sapiens 92-95